November 8, 2010

European Phase 2 Clinical Trial Evaluating WF10 as a Treatment for
Severe Allergic Rhinitis Meets its Primary Endpoint

MISSISSAUGA, ON, Nov. 8 /PRNewswire/ – Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company focused on the research and
development of drug products that are delivered into and through the
skin using its topical and transdermal drug delivery technologies and
on the development of its immune modulating drug candidate WF10, today
announced that its European Phase 2 clinical trial evaluating WF10 as a
treatment for severe allergic rhinitis met its primary endpoint.

“These top-line results support our view that WF10 has the potential to
become an effective treatment for patients with certain autoimmune
conditions, such as severe allergic rhinitis,” said Henrich Guntermann,
President, Europe & Immunology Group for Nuvo Research. “We will
evaluate the entire data set when it is available and consult with our
advisors to determine the optimal path forward to maximize the value of
WF10 for Nuvo and its shareholders.”

The randomized, double-blind, placebo-controlled, single-centre trial
assessed the efficacy and safety of WF10 infusions for the treatment of
patients with severe persistent allergic rhinitis. The trial enrolled
60 patients who have at least a two-year history of persistent allergic
rhinitis and who had a positive allergen skin test.

The trial met its primary endpoint as measured by the change in Total
Nasal Symptom Score (TNSS) from baseline to assessment after three
weeks comparing the WF10 group with the placebo group. The TNSS is a
validated scale to measure the aggregation of nasal symptoms associated
with allergic rhinitis. The p-value for the primary endpoint was less
than 0.001 for the intent-to-treat and per protocol groups.

No significant adverse events were observed during the trial, which was
conducted at a clinic site that specializes in airway diseases in
Leipzig, Germany.

About Allergic Rhinitis
Allergic rhinitis, also known as hay fever, causes cold-like symptoms
such as a runny nose, congestion and sneezing. Unlike a cold, allergic
rhinitis is not caused by a virus; it is caused by an allergic response
to airborne allergens such as pollen, pet dander or dust mites. The
condition affects about one in five people according to the Mayo

Severe allergic rhinitis is a more severe form of the condition and
often does not respond well to conventional treatments. Also, chronic
treatment with conventional drugs, e.g. corticosteroids, often causes
significant side effects.

Bank of Saxony
The Development Bank of Saxony in Germany is providing financial support
for this project that is being conducted in Germany through Nuvo
Research GmbH, a Nuvo subsidiary.

About WF10
The immune system provides an essential defense to micro organisms,
cancer and substances it sees as foreign and potentially harmful. WF10
focuses on supporting the immune system by targeting the macrophage, a
type of white blood cell that coordinates much of the immune system, to
regulate normal immune function. In conditions such as allergic
rhinitis, the body’s immune system inappropriately responds to the
presence of foreign allergens. Research suggests that in some cases,
WF10 may rebalance improperly functioning immune systems.

About Nuvo Research Inc.
Nuvo is primarily focused on the research and development of drug
products delivered into and through the skin using its topical and
transdermal drug delivery technologies, and on the development of its
immune modulating drug candidate WF10. Nuvo’s lead product is Pennsaid,
a topical non-steroidal anti-inflammatory drug (NSAID), which is sold
in Canada, the United States and several European countries. Pennsaid
was approved for marketing in the U.S. by the United States Food and
Drug Administration on November 4, 2009 and is being sold throughout
the United States by Nuvo’s licensing partner, Mallinckrodt Inc., a
Covidien (NYSE: COV) company. Nuvo intends to create a portfolio of
products through internal research and development and by in-licensing
and acquisition. Nuvo is a publicly traded, Canadian pharmaceutical
company headquartered in Mississauga, Ontario. Nuvo’s Pain Group is
located in West Chester, Pennsylvania. Its manufacturing facilities are
located in Varennes, Quebec and Wanzleben, Germany, and its research
and development centers are located in San Diego, California and
Leipzig, Germany. For more information, please visit www.nuvoresearch.com

Forward-Looking Statements

This document contains forward-looking statements. Some forward-looking
statements may be identified by words like “expects”, “anticipates”,
“plans”, “intends”, “indicates” or similar expressions. These
forward-looking statements, by their nature, necessarily involve risks
and uncertainties that could cause actual results to differ materially
from those contemplated by the forward-looking statements. Nuvo
considers the assumptions on which these forward-looking statements are
based to be reasonable at the time they were prepared, but caution that
these assumptions regarding future events, many of which are beyond the
control of the Company, may ultimately prove to be incorrect. Factors
and risks, which could cause actual results to differ materially from
current expectations, are discussed in the annual report, as well as in
Nuvo’s Annual Information Form for the year ended December 31, 2009.
Nuvo disclaims any intention or obligation to update or revise any
forward-looking statements whether a result of new information or
future events, except as required by law. For additional information on
risks and uncertainties relating to these forward looking statements,
investors should consult the Company’s ongoing quarterly filings,
annual report and Annual Information Form and other filings found on
SEDAR at www.sedar.com

SOURCE Nuvo Research Inc.

Source: newswire

comments powered by Disqus